Dementia biomarkers -- phosphorylated tau (P-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) - ...

A new study reveals that cognitive changes tied to Alzheimer's risk factors begin far earlier in life than previously thought, some as early as age 24.

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Oat milk is a nutritious alternative to dairy milk and may help reduce cholesterol levels thanks to its rich beta-glucan ...

Oat milk can be an important component of a heart-healthy eating plan. It is packed with beta-glucans, which create a gel-like consistency in the digestive system. This gel may help effectively ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

A one-year prospective study found no correlation between atherosclerosis and extremely high cholesterol levels in 100 ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...